Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Cells and Professor of Universities – Hospital Practitioner at Montpellier University Hospital, shared a post by Keerthi Kurma, Scientific Researcher at LCCRH -CHU de Montpellier, on LinkedIn, adding:
“Delighted to coordinate such a key project ‘Personalized immunotherapy using liquid biopsy and integration of research data for non-small cell lung cancer’ at the National Level.”
Quoting Keerthi Kurma’s post:
“We successfully held the Annual Meeting of the CURE project funded by Fondation ARC pour la recherche sur le cancer, bringing together collaborators from CHU de Montpellier, ICM – Institut du Cancer de Montpellier, Centre Hospitalier Universitaire de Nice (CHU de Nice), and Université de Montpellier.
The meeting focused on:
- Updates on circulating tumor DNA (ctDNA) analyses
- Circulating protein (CP) profiling using high-throughput proteomics
- Circulating tumor cell (CTC) detection and PD-L1 characterization
- Integration of multi-modal liquid biopsy data using artificialintelligence
CURE aims to develop an innovative predictive immunotherapy signature by integrating CTCs, ctDNA, and CP within a robust translational framework in NSCLC.
A sincere thank you to all collabrotors and people invovled, Catherine Alix-Panabières (coordinator), Keerthi Kurma, Zahra Eslami-S, Paul Hofman,Caroline Lacoux, Xavier Quantin, Quentin Thomas, Gérald Lossaint, Antoine Dujon, Caroline Mollevi, and Sandrine Tury for their strong engagement, scientific contributions, and collaborative spirit. The project continues to move forward with clear milestones and shared enthusiasm.
Looking forward to the next steps and upcoming data integration phases.”
Other articles featuring Catherine Alix-Panabières on OncoDaily.